<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924179</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-013-FLAG-C113</org_study_id>
    <nct_id>NCT04924179</nct_id>
  </id_info>
  <brief_title>Tislelizumab Combined With Surufatinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Oligometastatic CRC</brief_title>
  <official_title>A Phase II, Single-arm, Open-label, Single Center Study of Tislelizumab Combined With Surufatinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Oligometastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Study to Assess the Efficacy and Safety of Tislelizumab Combined With Surufatinib&#xD;
      and SBRT as Athird-line and Posterior Line Treatment in Patients With Oligometastatic&#xD;
      Colorectal Cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 16 months</time_frame>
    <description>To assess the efficacy of Tislelizumab Combined With Surufatinib and SBRT for patients with oligometastatic colorectal cancer by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 16 months</time_frame>
    <description>CR + PR rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 16 months</time_frame>
    <description>Disease control rate (DCR):CR + PR + SD rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The time interval between the start date of study drug and the date of death (any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Adverse reactions refer to the occurrence and development of diseases in the process of using drugs according to normal usage and dosage to prevent, diagnose or treat diseases.Adverse reactions unrelated to the purpose of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Patients With Advanced Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Tislelizumab plus Surufatinib and SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab plus Surufatinib and SBRT</intervention_name>
    <description>Surufatinib:250mg ,qd,po,21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.</description>
    <arm_group_label>Tislelizumab plus Surufatinib and SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written Informed Consent Form (ICF) prior to any study specific&#xD;
             procedures&#xD;
&#xD;
          2. Age ≥ 18 years, ≤75 years&#xD;
&#xD;
          3. Histologically or cytologically confirmed advanced Stage IV primary colorectal cancer&#xD;
&#xD;
          4. One or more organs metastases (oligometastases), and the metastases are suitable for&#xD;
             SBRT according to the evaluation of the researchers;&#xD;
&#xD;
          5. At least two or more standard systemic therapies prior treatment (based on Fu,&#xD;
             oxaliplatin, irinotecan, bevacizumab and cetuximab) of cytotoxic chemotherapy,&#xD;
             treatment failure or intolerable toxicities&#xD;
&#xD;
          6. ECOG 0-1&#xD;
&#xD;
          7. Patients must have measurable lesions&#xD;
&#xD;
          8. Expected overall survival ≥12 weeks&#xD;
&#xD;
          9. AST, ALT and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)，Serum&#xD;
             bilirubin ≤ 1.5 x ULN，creatinine&lt;ULN&#xD;
&#xD;
         10. Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN&#xD;
&#xD;
         11. Patients are allowed to have received radiotherapy, but the time from entering the&#xD;
             group must be more than 4 weeks, and the currently selected radiotherapy lesions and&#xD;
             evaluable lesions must be lesions that have not received radiotherapy&#xD;
&#xD;
         12. Women of childbearing age must be willing to use adequate contraceptives during the&#xD;
             study period of drug treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients have received anti-PD-1 / PD-L1 immunotherapy or other immunoexperimental&#xD;
             drugs&#xD;
&#xD;
          2. Patients with severe autoimmune diseases: active inflammatory bowel disease (including&#xD;
             Crohn's disease and ulcerative colitis), rheumatoid arthritis, scleroderma, systemic&#xD;
             lupus erythematosus, autoimmune vasculitis (such as Wegener's granuloma), etc&#xD;
&#xD;
          3. Risk factors of intestinal perforation: active diverticulitis, abdominal abscess,&#xD;
             gastrointestinal obstruction, abdominal cancer or other known risk factors of&#xD;
             intestinal perforation&#xD;
&#xD;
          4. Known hereditary or acquired bleeding (such as coagulation dysfunction) or thrombotic&#xD;
             tendency, such as hemophilia patients&#xD;
&#xD;
          5. Aspirin (&gt; 325 mg / day (maximum antiplatelet dose) or dipyridamole, ticlopidine,&#xD;
             clopidogrel (≥ 75 mg) and cilostazol are currently used or have been used recently&#xD;
             (within 10 days before the start of study treatment)&#xD;
&#xD;
          6. Thrombosis or embolism events such as cerebrovascular accident (including transient&#xD;
             ischemic attack, cerebral hemorrhage, cerebral infarction) and pulmonary embolism&#xD;
             occurred within 6 months before the start of the study&#xD;
&#xD;
          7. The researchers believe that the patient has a lesion and needs emergency palliative&#xD;
             radiotherapy / emergency surgery (spinal cord compression, brain hernia, pathological&#xD;
             fracture)&#xD;
&#xD;
          8. Known active infection and active tuberculosis infection were not included in the&#xD;
             group; However, patients with hepatitis B virus (HBV) and hepatitis C virus (HCV)&#xD;
             infection can be included in the group if their condition is stable after antiviral&#xD;
             treatment;&#xD;
&#xD;
          9. There is evidence of pneumoperitoneum that cannot be explained by puncture or recent&#xD;
             surgery;&#xD;
&#xD;
         10. Patients with history of hepatic encephalopathy;&#xD;
&#xD;
         11. Participated in the clinical trials of other drugs that have not been approved or&#xD;
             marketed in China and received the corresponding experimental drug treatment within 2&#xD;
             weeks before enrollment&#xD;
&#xD;
         12. systolic blood pressure &gt; 140mmHg or diastolic blood pressure &gt; 90mmHg regardless of&#xD;
             any antihypertensive drugs; Or patients need more than two antihypertensive drugs&#xD;
&#xD;
         13. Patients have untreated central nervous system metastasis&#xD;
&#xD;
         14. Received any operation or invasive treatment or operation (except venous&#xD;
             catheterization, puncture and drainage, etc.) within 4 weeks before enrollment&#xD;
&#xD;
         15. Patients have not recovered from all toxicities associated with prior anti-tumor&#xD;
             therapy ,to acceptable baseline status, or a National Cancer Institute Common&#xD;
             Terminology Criteria for Adverse Events(NCI CTCAE v5.0) Grade of 0 or 1, except for&#xD;
             alopecia and oxaliplatin induced neurotoxicity ≤ 2 , and the previous surgery did not&#xD;
             recover completely&#xD;
&#xD;
         16. Dysphagia or known malabsorption of drugs&#xD;
&#xD;
         17. Active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in GI&#xD;
&#xD;
         18. Have evidence or history of bleeding tendency within 2 months after enrollment, the&#xD;
             researcher assessed that moderate or severe bleeding tendency was not suitable for&#xD;
             enrollment&#xD;
&#xD;
         19. Patients had other malignant tumors in the past 5 years or at the same time (except&#xD;
             for the cured skin basal cell carcinoma and cervical carcinoma in situ);&#xD;
&#xD;
         20. Pregnant or lactating women&#xD;
&#xD;
         21. Allergic to Surufatinib/Vinorelbine&#xD;
&#xD;
         22. History of immunodeficiency, including HIV positive, other acquired or congenital&#xD;
             immunodeficiency diseases, or organ transplantation&#xD;
&#xD;
         23. Patients with acute myocardial infarction, severe / unstable angina pectoris or&#xD;
             coronary artery bypass grafting within 6 months before admission; Or a history of&#xD;
             arterial thrombosis or deep venous thrombosis&#xD;
&#xD;
         24. There are concomitant diseases (such as severe hypertension, diabetes, thyroid&#xD;
             disease, active infection, etc.) that seriously endanger the safety of patients or&#xD;
             affect the completion of the study, or any laboratory abnormalities that are not&#xD;
             suitable for participating in the clinical trial according to the judgment of the&#xD;
             researcher&#xD;
&#xD;
         25. Active autoimmune disease or history of autoimmune disease with possible recurrence&#xD;
             (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis,&#xD;
             enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism);&#xD;
&#xD;
         26. Immunosuppressive agents or systemic hormones were used 14 days before the start of&#xD;
             the study to achieve the purpose of immunosuppression (dose &gt; 10mg / day prednisone or&#xD;
             other therapeutic hormones)&#xD;
&#xD;
         27. Known to have a history of severe allergy to any monoclonal antibody or antiangiogenic&#xD;
             target drug&#xD;
&#xD;
         28. Serious psychological or mental disorders that may affect the compliance study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuan Xianglin</last_name>
    <phone>13667241722</phone>
    <email>xlyuan1020@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Yuan, PhD,MD</last_name>
      <phone>8627-83663406</phone>
      <email>xlyuan1020@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanmei Zou, PhD,MD</last_name>
      <phone>8627-83663406</phone>
      <email>zouyanmei0101@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xianglin Yuan</investigator_full_name>
    <investigator_title>Huazhong University of Science and Technology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

